A B S T R A C T Hypocalcemia is
A B S T R A C T Hypocalcemia is a frequent feature of hypomagnesemia in man and several other species. To elucidate the cause of this hypocalcemia, we have studied a child with primary hypomagnesemia and secondary hypocalcemia during magnesium supplementation when he was normomagnesemic and normocalcemic and after magnesium restriction for 16 days when he quickly became hypomagnesemic (0.5 meq/ liter) and hypocalcemic (3.4 meq/liter) and had positive Chvostek's and Trousseau's signs.
Whether in the normomagnesemic or hypomagnesemic state, intravenous bovine parathyroid extract (PTE) 8 U. S. P. U/kg promptly caused transient increases in the urinary phosphate excretion, renal phosphate clearance and cyclic AMP excretion. The magnitudes of these responses were similar in the two states, and similar to those observed in a hypoparathyroid patient. When the patient was hypomagnesemic and hypocalcemic, intramuscular PTE, 8 U/kg at 8-h intervals for four doses promptly caused hypercalcemia. The findings indicate that the end-organs were responsive to parathyroid hormone.
The concentrations of serum parathyroid hormone (PTH) were normal in the normomagnesemic state ranging from 0.15 ng/ml to 0.40 ng/ml. Serum PTH did not increase in the hypomagnesemic state in spite of hypocalcemia. Indeed, PTH became unmeasurable in A preliminary report of this work has been published as an abstract (1) .
INTRODUCTION
In recent years, there has been interest in a condition called primary hypomagnesemia with secondary hypocalcemia (2) (3) (4) (5) . Convulsions are the presenting problem and severe hypomagnesemia and hypocalcemia are the two prominent abnormal biochemical findings. Onset is in the neonatal period. The defect is frequently persistent. Administration of magnesium promptly abolishes the symptoms, corrects hypocalcemia, and constitutes an effective long-term treatment. The basis of the defective magnesium homeostasis is still in question, but defective intestinal absorption of magnesium is the most likely cause.
The etiology of the hypocalcemia in primary hypomagnesemia is also not known. The present study was carried out in a child with this condition to elucidate the pathophysiology of this biochemical abnormality. Among the causes that might result in hypocalcemia are end-organ refractoriness to parathyroid hormone, de- 5 .0 meq/liter, and 4.1 mg/10 ml, respectively. Serum parathyroid hormone ranged from 0.15 to 0.40 ng/ml (normal range for our immunoassay < 0.15-0.60 ng/ml) and serum calcitonin was unmeasurable (< 0.10 ng/ml) (normal range < 0.10-0.38 ng/ml). The plasma sodium, potassium, and chloride, and the blood pH were normal.
METHODS
Experimental design. The experimental design is summarized in Table I . Throughout the study, the patient con1Magnesium chloride (MgCl2 6H20) 40.0 g; magnesium citrate, dibasic (MgHCeH507 5H20) 60.0 g; water to 1,000 ml. This solution provides approximately 0.8 meq magnesium per ml.
2 The protocol for this investigation was accepted by the sumed a constant diet consisting of natural foods of low magnesium content providing 5 meq of magnesium per day. 3 The study was carried out in two phases: while the patient received a high magnesium intake (90 meq/day) achieved by supplementing with 85 meq of magnesium daily (49 days), and while he received a low magnesium intake (5 meq/day) achieved by withholding the magnesium supplements (16 days). Magnesium supplementation was then reinstituted. Serum parathyroid hormone (PTH) ' and calcitonin concentrations were determined frequently throughout the study. The renal response to PTH was assessed in both phases of magnesium intake, and the calcemic response to PTH was assessed at the end of the period of low magnesium intake when the patient was severely hypomagnesemic and hypocalcemic.
Assessment of renal response to parathyroid hormone. Renal response to parathyroid hormone was assessed by determining renal phosphate handling and urinary excretion of adenosine 3',5'-monophosphate (cyclic AMP) before and after intravenous injection of bovine parathyroid extract (PTE). The assessment was carried out in both phases of magnesium intake (Table I) . Food was withheld during each test, commencing the previous evening. 2 h before starting urine collection, the-patient was required to drink water, 20 ml/kg body wt, to induce diuresis. Subsequently, water intake was matched to urine output until the end of the test. Blood samples were obtained hourly throughout the test, and analyzed for inorganic phosphate and creatinine concentrations. Urine was collected hourly for 4 h, then PTE was injected and thereafter urine was collected halfhourly for 1 h and hourly for the remaining 3 h of the Committee on Human Experimentation of the University of Toronto and the implications were discussed in detail with the parents.
'This diet also provided relatively small amounts of calcium (13 meq), sodium (40 meq), potassium (24 meq), and phosphorus (420 mg) daily. However, the diet did not alter the patient's plasma concentrations of these minerals from the normal levels observed while he consumed regular foods.
'Abbreviations used in this paper: Cr creatinine clearance; Cp, renal phosphate clearance; CT, calcitonin; PTE, bovine parathyroid extract; PTH, parathyroid hormone; %TRP, percentage of filtered phosphate reabsorbed by renal tubules; UCe-AMP, urinary cyclic AMP excretion rate; Up, urinary phosphate excretion rate.
test. Urine specimens were frozen at -20°C immediately after collection and subsequently analyzed for phosphate, cyclic AMP, and creatinine. The dose of PTE5 was 8 U.S.P. U/kg body weight (total 160 U) diluted in 50 ml normal saline and injected intravenously over a 10 min period.
Urinary phosphate excretion rate (Up), renal phosphate clearance (C,), the percentage of filtered phosphate reabsorbed by the renal tubules (%oTRP), creatinine clearance (Cc.), and urinary cyclic AMP excretion rate (Uc-AMP) were determined for each of the nine collection periods. Assessment of calcemic response to parathyroid hormone. The calcemic response to PTE was assessed only while the patient was in the hypomagnesemic, hypocalcemic phase. Immediately following assessment of renal response to parathyroid hormone, that is 4 h after the intravenous PTE injection, PTE was administered intramuscularly (8 U/kg, 160 U/dose) every 8 h until the patient became hypercalcemic. Concentrations of plasma total and ionized calcium, and inorganic phosphate were measured 4 h after each dose of PTE.
Radioimmunoassay of parathyroid hormone. Serum PTH concentrations were measured by immunoassay (7), using an antiserum that gives greater sensitivity than the one described in the original report. The assay detects 0.15 ng of bovine PTH equivalent per milliliter of human serum. In each case, the recorded PTH concentration represents the mean of two separate determinations. Concentrations in plasma or serum from 200 normal, fasting humans ranged from unmeasurable (<0.15 ng/ml) in 35% of subjects to 0.60 ng/ml (8) . The range of serum PTH in children (ages 1-17 yr) did not differ significantly from that measured in adult subjects. No differences were detected between plasma and serum samples.
The following physiological observations confirm the validity of this immunoassay for human PTH:
(a) Serum PTH levels were at or above the upper limit of normal (0.60 ng/ml) in most individuals in the following groups of patients with hypocalcemia (Table II) : (1) pseudohypoparathyroidism (four of six cases); (2) vitamin D-deficient rickets (two of two cases); (3) vitamin D-dependent rickets (one of two cases); (4) "dilantin rickets" (three of four cases); and (5) chronic renal insufficiency (12 of 15 cases).
(b) In one child with chronic renal insufficiency, infusion of EDTA for 2 h at a rate sufficient to lower the noncomplexed serum calcium concentration from 5.8 to 52 meq/ liter caused an increase in serum PTH from 1.0 to 1.5 ng/ml. Serum PTH then decreased progressively to 0.60 ng/ml during a 4 h calcium infusion that increased the serum calcium to 6.1 meq/liter.
(c) The serum PTH concentration was greater than 0.60 ng/ml in 43 of 61 patients with surgically confirmed parathyroid adenoma or hyperplasia. The remaining patients had values between 0.30 and 0.60 ng/ml.
(d) Serum PTH increased from an unmeasurable concentration to 0.53 ng/ml when PTE was administered intramuscularly to our patient with primary hypomagnesemia in a dose sufficient to overcome hypocalcemia (Fig. 1, May  30) .
(e) Serum PTH concentrations in our patient with primary hypomagnesemia decreased from 0.32 ng/ml to unmeasurable levels (two consecutive samples) when the sPara-Thor-Mone. Batch no. AL3KX75A, Eli Lilly & Co., Indianapolis, Ind. (9) . When the patient was fed the low magnesium intake, the plasma concentrations of magnesium decreased steadily and reached 0.5 meq/liter by the 16th day of magnesium restriction ( Fig. 1, May 28) . The concentrations of total and ionized calcium remained normal during the 1st wk of the low magnesium intake, then declined steadily, reaching 3.4 and 1.6 meq/liter, respectively, on the 16th day. Plasma inorganic phosphate NORMOMAGNESEMIC STATE increased from 4.0 to 5.7 mg/100 ml (not shown). Because the Chvostek and Trousseau tests became strongly positive, magnesium restriction was not continued beyond the 16th day. The concentrations of serum PTH, determined several times while the patient was hypomagnesemic and hypocalcemic, remained low, and in the last four samples at the end of the period of magnesium restriction, PTH was unmeasurable.
Calcemic response to PTE. Just before ending the period of magnesium restriction, when the patient was severely hypomagnesemic and hypocalcemic, administration of five doses of PTE during a 28 h period increased the plasma calcium from 3.4 to 6.2 meq/liter and the ionized calcium from 1.6 to 2.7 meq/liter. Inorganic phosphate fell progressively from 5.7 to 4.0 mg/100 ml. The concentration of magnesium increased only slightly, from 0.50 to 0.64 meq/liter.
Renal responses to PTE. Fig. 2 shows the renal responses to PTE in the normomagnesemic and hypomnagnesemic phases. While the patient was normomagne- mg/100 ml. During low magnesium intake, plasma Mg was 0.5 meq/liter, Ca 3.4 meq/liter, and Pi 5.7 mg/100 ml. meq of magnesium intramuscularly to help replace his magnesium deficit and the high magnesium intake was again provided. The plasma magnesium and calcium concentrations returned to normal promptly. Serum PTH was 0.45 ng/ml, 33 h after his last intramuscular dose of PTE.
Concentrations of other electrolytes. Values of plasma sodium, potassium, chloride, and pH remained normal throughout all phases of the study.
DISCUSSION
Although it has been established that the hypocalcemia characteristic of hypomagnesemic syndromes is caused by the magnesium deficiency per se (2, 12, 13) , the pathophysiological mechanism for the deranged calcium homeostasis has not been explained. A frequently suggested explanation is refractoriness of the end-organs to parathyroid hormone, implying a disturbance analogous to that proposed in pseudohypoparathyroidism. Table IV summarizes published data on end-organ responsiveness to parathyroid hormone in magnesium depletion. In magnesium-depleted rats, several studies showed normal calcemic (14) (15) (16) and renal (16) responses to PTE. In the study of MacManus, Heaton, and Lucas (17) , bone of magnesium-depleted rats was reported to show diminished responsiveness to PTE in vivo and in vitro, but the significance of the findings is open to question because the increase of plasma calcium in response to PTE in the control rats was unusually small and because the use of nonfetal bone shafts in the in vitro experiment does not provide optimal conditions for action of parathyroid hormone. In puppies (6) and monkeys (18) , quantitative comparisons indicated that the calcemic responses of magnesium-depleted animals were equal to those of magnesium-supplemented controls. In the human, hypomagnesemic adults with chronic alcoholism or steatorrhea were refractory to the calcemic action of PTE (19) (20) (21) (22) ; response to the phosphoraturic action of PTE was variable (no response [19, 20] , partial response [21] or full response [22] ). Because alcoholism and steatorrhea may cause complicated nutritional deficiencies, factors other than magnesium deficiency may have been involved in the PTH refractoriness of patients with these conditions. By contrast, in primary hypomagnesemia, our patient showed a clear-cut calcemic response to PTE when he was severely hypomagnesemic and hypocalcemic (reference 2, and present paper). This finding is in agreement with those in other children with this condition (3) (4) (5) 23) . Furthermore, in the present study and in that of Anast, Mohs, Kaplan, and Burns (23), the kidney, a target organ for parathyroid hormone, was responsive to PTE, as indicated by increases in urinary phosphate and cyclic AMP excretion; indeed, the degree of responsiveness was equal to that observed when he was normomagnesemic. Thus, hypocalcemia in primary hypomagnesemia cannot be readily accounted for by refractoriness to parathyroid hormone.
An alternative explanation for the hypocalcemia is parathyroid gland dysfunction and the serial measurements of circulating parathyroid hormone obtained in the present study provide direct evidence about this aspect. From physiological principles, hypocalcemia would normally be expected to stimulate increased secretion of parathyroid hormone. Yet, though our patient with primary hypomagnesemia became sufficiently hypocalcemic during magnesium restriction to exhibit positive Trousseau and Chvostek signs, his serum PTH did not rise; on the contrary, parathyroid hormone was no longer measurable by the end of the period of magnesium restriction. Our immunoassay was of sufficient sensitivity 158 to demonstrate increased circulating PTH in the majority of individuals with hypocalcemia of various causes. We interpret the observations in our hypomagnesemic patient to indicate that magnesium depletion resulted in impairment of synthesis or secretion of parathyroid hormone, causing, in effect, a form of hypoparathyroidism. This hypothesis fits our other observations in the patient during the phase of magnesium depletion-hypocalcemia, increasing plasma phosphate concentrations, unimpaired end-organ responsiveness to parathyroid hormone, no increase in the baseline rate of urinary cyclic AMP excretion (the last has been shown to increase in hyperparathyroid states [24] [25] [26] ). Observations in magnesium-depleted puppies had previously led us to propose impaired PTH synthesis or secretion as the likely cause for hypocalcemia in that species (6) . Recently, Anast et al. (23) have arrived independently at the same conclusion in an adolescent girl with chronic hypomagnesemia on the basis of results that are very similar to ours (27) .
Theoretically, excess calcitonin secretion should be considered as a possible cause of hypocalcemia, and Rojo-Ortega, Bracht, and Genest (28) have advanced this thesis to explain their findings in magnesium-depleted dogs. We have previously presented our evidence in puppies against this theory (6) . The finding in our patient that circulating calcitonin was consistently less than 0.10 ng/ml during the period of hypocalcemia provides direct evidence that the C cells do not play a role in the hypocalcemia of magnesium depletion.
